Erlmeier, F.; Sun, N.; Shen, J.; Feuchtinger, A.; Buck, A.; Prade, V.M.; Kunzke, T.; Schraml, P.; Moch, H.; Autenrieth, M.;
et al. MALDI Mass Spectrometry Imaging—Prognostic Pathways and Metabolites for Renal Cell Carcinomas. Cancers 2022, 14, 1763.
https://doi.org/10.3390/cancers14071763
AMA Style
Erlmeier F, Sun N, Shen J, Feuchtinger A, Buck A, Prade VM, Kunzke T, Schraml P, Moch H, Autenrieth M,
et al. MALDI Mass Spectrometry Imaging—Prognostic Pathways and Metabolites for Renal Cell Carcinomas. Cancers. 2022; 14(7):1763.
https://doi.org/10.3390/cancers14071763
Chicago/Turabian Style
Erlmeier, Franziska, Na Sun, Jian Shen, Annette Feuchtinger, Achim Buck, Verena M. Prade, Thomas Kunzke, Peter Schraml, Holger Moch, Michael Autenrieth,
and et al. 2022. "MALDI Mass Spectrometry Imaging—Prognostic Pathways and Metabolites for Renal Cell Carcinomas" Cancers 14, no. 7: 1763.
https://doi.org/10.3390/cancers14071763
APA Style
Erlmeier, F., Sun, N., Shen, J., Feuchtinger, A., Buck, A., Prade, V. M., Kunzke, T., Schraml, P., Moch, H., Autenrieth, M., Weichert, W., Hartmann, A., & Walch, A.
(2022). MALDI Mass Spectrometry Imaging—Prognostic Pathways and Metabolites for Renal Cell Carcinomas. Cancers, 14(7), 1763.
https://doi.org/10.3390/cancers14071763